State Street’s First Tracks Biotherapeutics TRAX Stock Holding History

State Street’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$57.1M	Buy	1,610,805 +97,909	+6%	+$3.82M	﹤0.01%	1747
2026 Q2	$30.4M	Buy	+1,512,896	New	+$28.3M	﹤0.01%	2162

Other funds holding TRAX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

State Street's TRAX Position: Q3 2026 in Review

State Street increased its First Tracks Biotherapeutics (TRAX) stake by 6.5% in Q3 2026, buying an estimated $3.82M and bringing the position to 1,610,805 shares worth $57.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

State Street first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

State Street held 1,610,805 shares of First Tracks Biotherapeutics worth $57.1M as of Q3 2026.
State Street bought 97,909 First Tracks Biotherapeutics shares in Q3 2026, an estimated $3.82M.
First Tracks Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #1747 holding.
State Street first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.